Equities Analysts Set Expectations for CMPS Q3 Earnings

Key Points

• HC Wainwright has lowered its earnings estimates for COMPASS Pathways, expecting Q3 2025 earnings per share to be ($0.44), down from a previous estimate of ($0.38).
• Despite the downgrade, HC Wainwright maintains a "Buy" rating and a price objective of $40.00 for COMPASS Pathways stock.
• The company reported an earnings miss for Q2, with earnings per share of ($0.38), which was below the consensus estimate of ($0.37).

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) - Equities researchers at HC Wainwright decreased their Q3 2025 earnings per share estimates for shares of COMPASS Pathways in a research note issued to investors on Monday, August 4th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.44) per share for the quarter, down from their previous estimate of ($0.38). HC Wainwright has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for COMPASS Pathways' current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for COMPASS Pathways' Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.68) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.91) EPS, FY2027 earnings at ($0.96) EPS, FY2028 earnings at ($0.18) EPS and FY2029 earnings at $1.00 EPS.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01).

Other analysts have also recently issued reports about the company. Canaccord Genuity Group reissued a "buy" rating and issued a $15.00 price target on shares of COMPASS Pathways in a research report on Friday, August 1st. Evercore ISI reissued an "in-line" rating and issued a $6.00 price target (down from $11.00) on shares of COMPASS Pathways in a research report on Monday, June 23rd. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $12.00 price target on shares of COMPASS Pathways in a research report on Tuesday, May 27th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $16.29.

COMPASS Pathways Stock Down 2.4%

COMPASS Pathways stock traded down $0.10 during trading hours on Thursday, hitting $4.29. 1,101,459 shares of the stock traded hands, compared to its average volume of 1,813,944. The company has a current ratio of 8.82, a quick ratio of 8.82 and a debt-to-equity ratio of 0.16. The firm's 50-day moving average price is $4.01 and its two-hundred day moving average price is $3.83. COMPASS Pathways has a one year low of $2.25 and a one year high of $8.54. The company has a market cap of $411.20 million, a PE ratio of -2.34 and a beta of 2.17.

Institutional Trading of COMPASS Pathways

Several institutional investors have recently added to or reduced their stakes in CMPS. RTW Investments LP bought a new stake in COMPASS Pathways in the fourth quarter worth about $11,714,000. Nantahala Capital Management LLC raised its stake in shares of COMPASS Pathways by 182.9% during the first quarter. Nantahala Capital Management LLC now owns 2,829,232 shares of the company's stock valued at $8,092,000 after acquiring an additional 1,829,232 shares in the last quarter. Vivo Capital LLC raised its stake in shares of COMPASS Pathways by 109.1% during the first quarter. Vivo Capital LLC now owns 3,362,385 shares of the company's stock valued at $9,616,000 after acquiring an additional 1,754,385 shares in the last quarter. Altium Capital Management LLC bought a new stake in shares of COMPASS Pathways during the fourth quarter valued at approximately $5,384,000. Finally, Woodline Partners LP raised its stake in shares of COMPASS Pathways by 279.9% during the first quarter. Woodline Partners LP now owns 1,754,856 shares of the company's stock valued at $5,019,000 after acquiring an additional 1,292,927 shares in the last quarter. Institutional investors own 46.19% of the company's stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.